Rockville, Jan. 04, 2023 (GLOBE NEWSWIRE) -- A new industry analysis by Fact.MR, a market research and competitive intelligence provider, says that the global structural heart devices market is valued at US$ 12.17 billion in 2023 and is predicted to reach US$ 36.06 billion by the end of 2033.
Structural heart disease is a broad term describing a type of percutaneous therapy used to treat patients with congenital and inherited heart conditions that involve functional and structural abnormalities in the heart valves, proximal great arteries, and heart chambers. Due to wear and tear from infections, these diseases may manifest later in life but may also be present from birth.
Primary factors boosting the sales of structural heart devices are the rising prevalence of structural heart diseases, the surge in enlarged indication approval for numerous transcatheter structural heart products, and the rise in the senior population affected by various degenerative valvular heart diseases. Growing preference for minimally-invasive structural heart therapeutic products among patients who place a premium on value and the increase in research and development spending for the creation of cutting-edge, innovative products all contribute to the market growth for structural heart devices.
On the other hand, it is expected that constraints such as low accessibility and low affordability of cardiac procedures in emerging nations may somewhat impede the demand for structural heart devices in poor and developing economies.
Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=8136
The global market is dominated by North America due to the high rate of minimally-invasive procedures and rising endovascular procedure rates. Asia Pacific is anticipated to experience a high CAGR over the projected period due to advancements in screening programmes, rising heart disease awareness among the populace, and improved access to healthcare systems.
Key Takeaways from Market Study
- Global demand for structural heart devices is expected to increase at a CAGR of 11% from 2023-2033.
- China’s market is predicted to expand at a CAGR of 10% during the projected period.
- Sales of heart valve devices are expected to rise at a CAGR of 11.5% during the forecast period.
- Demand for surgical heart valves is predicted to expand at a CAGR of 11% during the next 10 years.
“Highest demand for structural heart devices to be exhibited by hospitals as compared to other types of medical centers,” says a Fact.MR analyst.
Segments of Structural Heart Devices Industry Research
- By Product :
- Heart Valve Devices
- Surgical Heart Valves
- Transcatheter Heart Valves
- Occluders & Delivery Systems
- By Procedure:
- Replacement Procedures
- Repair Procedures
- By Age Group :
- Pediatrics
- Adults
- Geriatrics
- By Indication :
- Atrial Septal Defect (ASD)
- Ventricular Septal Defect (VSD)
- Patent Foramen Ovale (PFO)
- Aortic Valve Stenosis
- By End User :
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Centers
- By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Get Customization on this Report for Specific Research Solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=8136
Winning Strategy
The structural heart devices market is highly competitive and consists of significant market players, including Abbott Laboratories, Boston Scientific Corporation, Braile Biomedica, CryoLife, Inc., Edwards Lifesciences Corporation, and others.
- Medtronic introduced the transcatheter aortic valve replacement (TAVR) system Evolut PRO+ in the United States in September 2019.
- The MITRIS RESILIA valve was approved by the US Food and Drug Administration (FDA) in March 2022 for Edwards Lifesciences. It is a tissue valve replacement made especially for the mitral location of the heart.
Competitive Landscape
Leading companies are embracing novel strategies to increase their market share, including cutting-edge marketing tactics, technological breakthroughs, mergers, and acquisitions.
- Abbott Laboratories unveiled a novel, minimally-invasive vascular heart valve repair device in May 2022. New information was also provided by the company about Amplatzer Amulet and MitraClip, two essential items in its market-leading Abbott structural heart devices portfolio.
- For instance, Centerline Biomedical, Inc. finished the second animal study in a series on structural heart navigation in May 2022. The viability of using the company's augmented reality picture guidance technology to navigate structures in a beating heart was assessed by doctors from Cleveland Clinic's Heart, Vascular and Thoracic Institute.
- In 2022, Medtronic Inc. announced that it will purchase Affera, a company that develops therapies for cardiac arrhythmias. This acquisition is probably going to increase the company's portfolio of heart ablation procedures, allowing for the development of maps to identify arrhythmias. This will also increase the Medtronic structural heart device offerings.
Key Companies Profiled
- Abbott Laboratories, Inc.
- Boston Scientific Corporation
- Braile Biomedica
- CryoLife, Inc.
- Edwards Lifesciences Corporation
- Lepu Medical Technology (Beijing) Co., Ltd.
- LivaNova PLC
- Medtronic PLC
- Micro Interventional Devices, Inc.
- TTK Healthcare Ltd.
Explore Our Safe & Secure Payment Options for Quick Buy – https://www.factmr.com/checkout/8136
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global structural heart devices market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.
The study divulges essential insights on the market on the basis of product (heart valve devices, surgical heart valves, transcatheter heart valves, occluders & delivery systems), procedure (replacement procedures, repair procedures), age group (pediatrics, adults, geriatrics), indication (atrial septal defect (ASD), ventricular septal defect (VSD), patent foramen ovale (PFO), aortic valve stenosis), and end user (hospitals, ambulatory surgical centers, cardiac centers), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out more related studies published by Fact.MR Research:
Cardiopulmonary Stress Testing Systems Market: Global cardiopulmonary stress testing devices market is poised to expand positively at a CAGR of 4.8% during the forecast period (2020-2025). Cardiovascular Disease (CVD) remains one of the leading causes of death across the world.
Cardiac POC Testing Devices Market: Worldwide sales of cardiac POC testing devices are anticipated to increase rapidly at a CAGR of 6% from 2022 to 2026. In 2022, the global cardiac POC testing devices market is valued at US$ 1.5 billion and is projected to reach a market size of US$ 1.9 billion by 2026.
Cannula Market: Worldwide sales of cannulas are predicted to accelerate at a CAGR of 6.2% from 2022 to 2027. In 2022, the global cannula market is valued at US$ 185 million and is projected to reach a market size of US$ 250 million by 2027.
Cardiology Genomic Testing Market: Heart disorders can be inherited and passed from parents to children via their genes. Cardiology genomic testing helps in detecting diseases such as aortopathy and congenital heart diseases. Also, it can be useful for family members who are at a risk of developing heart problems.
Heart Attack Diagnostics Market: The heart attack diagnostics market share is predicted to grow at a moderate CAGR of 7.1% during the forecast period of 2023 to 2033. The global heart attack diagnostics market is estimated to reach a value of nearly US$ 23.8 Billion by 2033 growing from US$ 12 Billion in 2023.
About Us:
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Tel: +1 (628) 251-1583
